论文部分内容阅读
目的:分析美罗华对CD20阳性非霍奇金淋巴瘤(NHL)患者血清乳酸脱氢酶(LDH)、β2-微球蛋白(β2-MG)水平及预后的影响。方法:对2004年1月-2011年6月在我院收治的86例NHL患者,分别采用CHOP(对照组,n=48)与RCHOP(治疗组,n=48)2种不同的方案进行化疗,每21天为一个周期,共6个周期。比较两组临床疗效、不良反应、LDH和β2-MG水平变化及预后。结果:治疗组的ORR和DCR分别为77.1%和89.6%,均显著高于对照组56.3%和72.9%(P<0.05);化疗后,两组血清LDH、β2-MG均较化疗前明显下降,而治疗组化疗后血清LDH、β2-MG均显著低于对照组(P<0.05);治疗组白细胞减少、恶心呕吐的并发症高于对照组(P<0.05);化疗后1、2年生存率两组之间均无显著性差异(P>0.05),而治疗组化疗后3年生存率明显升高(P<0.05)。结论:美罗华联合CHOP方案治疗CD20阳性NHL患者疗效明显,且耐受性好,可有效调节血清LDH、β2-MG水平,提高缓解率,改善患者预后。
Objective: To analyze the effect of rituximab on the levels of serum lactate dehydrogenase (LDH), β2-microglobulin (β2-MG) and prognosis in patients with CD20 positive non-Hodgkin’s lymphoma (NHL). Methods: Eighty-six NHL patients admitted to our hospital from January 2004 to June 2011 were enrolled in this study. Two different regimens, CHOP (n = 48) and RCHOP (n = 48) , Every 21 days for a cycle, a total of 6 cycles. The clinical efficacy, adverse reactions, LDH and β2-MG levels and prognosis were compared between the two groups. Results: The ORR and DCR of the treatment group were 77.1% and 89.6%, respectively, which were significantly higher than those of the control group 56.3% and 72.9% (P <0.05). After chemotherapy, the levels of serum LDH and β2-MG were significantly decreased , While the serum LDH and β2-MG in the treatment group were significantly lower than those in the control group (P <0.05). The complication of leukopenia and nausea and vomiting in the treatment group was higher than that in the control group (P <0.05) There was no significant difference in survival between the two groups (P> 0.05), but the 3-year survival rate of the treatment group was significantly higher (P <0.05). Conclusion: The combination of rituximab and CHOP regimen in patients with CD20-positive NHL has obvious curative effect and good tolerance, which can effectively regulate serum LDH and β2-MG levels, improve remission rate and improve prognosis.